Yeh I picked up a number of mistakes as well. The ones I noticed though (and the one you noticed) all meant DCF was understating price. There were probably ones I missed that caused an overstating no doubt as well. Given that is todays price it still makes for interesting comparison to where we are at instead.
Started with:
I'd like a thorough analysis of Neuren Pharmaceutical stock, including:
Summary: Company overview, key metrics, performance data and investment recommendations
Financial Data: Revenue trends, profit margins, balance sheet and cash flow analysis
Market Sentiment: Analyst ratings, sentiment indicators and news impact
Technical Analysis: Price trends, technical indicators and support/resistance levels
Compare Assets: Market share and financial metrics vs. key competitors
Value Investor: Intrinsic value, growth potential and risk factors
Investment Thesis: SWOT analysis and recommendations for different investor types.
Please incorporate graphical components like charts/tables/graphs where appropriate.
And then I did
Can you do a detailed analysis of the potential revenue to be generated from NNZ-2591 for each of the different indications so far targeted (PMS, PHS, Angelmans, HIE).
And then I did
Can you provide a DCF price for Neuren pharmaceuticals based on this report including expected revenue for Daybue in coming years and add this to the above report and retitle Cashflow forecast and valuation for Neuren pharmaceuticals
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)